Spero Therapeutics Inc

This management proposal requests a non-binding advisory approval of the Company’s named executive officer compensation as disclosed in the proxy materials (a standard “say-on-pay” vote). Management frames compensation as aligned with a pay-for-performance philosophy, with significant equity components and bonuses tied to corporate and program milestones (including outcomes under the GSK collaboration and PIVOT-PO trial results). The vote is advisory only, but the Compensation Committee and Board state they will review and consider the voting results in setting future compensation. Key context includes recent retention bonuses and RSU grants to executives described in the proxy, the Company’s recent operational milestones (e.g., PIVOT-PO meeting endpoint and NDA resubmission activities with GSK), and the Board’s use of an independent compensation consultant. The Board recommends a vote “FOR” because it believes the packages incentivize management to deliver on near-term regulatory and commercial objectives while aligning long-term shareholder returns via equity. Potential shareholder concerns include the level and structure of retention bonuses, severance protections in executive employment agreements, and equity dilution impacts; however, management emphasizes performance metrics and clawback and other governance features that mitigate risk. Although non-binding, a substantial negative vote would typically prompt the Compensation Committee to engage with shareholders and consider substantive changes to compensation practices. For institutional investors evaluating the proposal, the decision hinges on whether the disclosed pay design sufficiently links compensation to realized value creation and whether governance protections and disclosure provide adequate oversight and alignment.

This management proposal asks shareholders to approve a Certificate of Amendment to double the Company’s authorized common stock to 240 million shares (raising total authorized shares to 250 million including preferred). Management seeks this authorization to provide corporate flexibility — to support equity compensation, potential financings, collaborations, strategic transactions, and other corporate purposes — without the delay and expense of a separate shareholder approval for each issuance. The Board emphasizes that no specific plan exists to issue all additional shares at this time, and notes existing reserves (outstanding shares, awards, and ATM capacity) to contextualize current needs. The potential effects include dilution of existing holders’ percentage ownership and voting power and possible downward pressure on stock price if large issuances occur; the proxy discusses these dilutive risks and notes the Board did not propose the increase to specifically deter takeovers. From a governance perspective, investors will weigh the trade-off between management’s need for operational flexibility and the risk that a large authorized but unissued pool could be used opportunistically, and some institutional investors prefer share increases accompanied by explicit use limitations or pre-commitments. The Board’s recommendation “FOR” is grounded in expected near-term capital needs (including advancing tebipenem-related opportunities under the GSK collaboration) and the desire to preserve optionality for compensation and strategic transactions. Sophisticated analysts should evaluate the Company’s stated near-term financing runway, historical share usage, and governance safeguards (e.g., no pre-approval to issue shares for anti-takeover purposes) to judge whether the requested authorization is appropriate.

This proposal seeks shareholder approval of a successor equity plan (the 2026 Plan) to replace the expiring 2017 Plan and preserve the Company’s ability to grant equity awards to employees, directors and consultants. Critically, the Company is not requesting any additional new shares; the proposed reserve equals the Current Plan’s unused shares plus shares subject to outstanding awards that may become available upon cancellation or forfeiture (aggregate up to 12,846,699 shares). Management argues the plan is necessary to compete for talent, align employees’ interests with stockholders through equity ownership, and avoid raising cash compensation materially. The 2026 Plan contains stockholder-friendly features — no evergreen replenishment, no repricing without stockholder approval, restrictions on liberal recycling of shares, dividend-equivalent controls, limits on non-employee director annual compensation, and clawback rights — which the Board cites as governance protections. Analysts should evaluate the expected burn rate and overhang (the filing discloses historical burn rates and a current overhang of ~26.2%) against peer benchmarks to assess whether the reserve is appropriate. Because the Company expects to continue using inducement awards for new hires, the plan’s share pool is calibrated to cover expected grants for several years at historical usage levels; however, actual longevity depends on future hiring, equity grant sizes, and stock price movements. The Board recommends a vote “FOR” on the basis that the 2026 Plan preserves compensation flexibility while incorporating features intended to protect shareholder interests.